Precision Brain Access for Deep Brain Therapies
Millions of patients with Parkinson’s disease, Alzheimer’s disease, brain cancer, epilepsy, and other neurological disorders depend on therapies that must reach precise locations within the brain to be effective. NeuralGlider® is a validated precision brain access platform designed to improve target accuracy and support more effective delivery of brain-directed therapies.
THE BOTTLENECK
The Bottleneck in Brain Therapeutics Is Not Only Biology — It Is Delivery
Breakthrough brain therapies are advancing rapidly, but their success depends on accurate delivery to precise brain targets. Even when the biological target is validated and the therapeutic payload is effective, clinical benefit can be limited if the therapy, implant, or device does not reach its intended location.
Actuated Medical is addressing this fundamental challenge with a developed and validated platform for precision brain access.
THE PLATFORM
Introducing the NeuralGlider® Precision Brain Access Platform
The NeuralGlider® platform uses electronically controlled ultrasonic motion to help maintain the desired trajectory during insertion through delicate brain tissue. In preclinical studies, it demonstrated precise delivery a AAV gene therapy to deep brain targets using a smaller-diameter cannula that showed healthier brain cells at the insertion site and less drug loss wicking back up the insertion track.
- NHelps maintain the desired trajectory during insertion
- NSupports precise access to deep brain targets
- NPermits smaller-diameter cannulas for certain delivery applications
- NReduces tissue trauma and therapeutic reflux
- NEnables improved delivery across multiple brain-directed therapy categories